Novavax, Inc.

NVAX

US6700024010

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:40:59 2024-07-16 pm EDT			5-day change	1st Jan Change
16.28 ^USD	+7.67%		+37.37%	+238.85%

Jul. 15	Second malaria vaccine launched in Ivory Coast in new milestone	RE
Jul. 02	Novavax Seeks Health Canada Approval for Updated Covid-19 Vaccine	MT

Novavax : An experimental COVID-19 vaccine from Novavax appears to offer strong protection in late-stage UK, South Africa studies

January 28, 2021 at 04:10 pm EST

WASHINGTON (AP) — An experimental COVID-19 vaccine from Novavax appears to offer strong protection in late-stage UK, South Africa studies.

Latest news about Novavax, Inc.

Second malaria vaccine launched in Ivory Coast in new milestone	Jul. 15	RE
Novavax Seeks Health Canada Approval for Updated Covid-19 Vaccine	Jul. 02	MT
Novavax: Health Canada approves Covid 24/25 vaccine	Jul. 02	CF
Novavax: ACIP in favor of Covid 24/25 vaccine	Jun. 28	CF
US CDC advisers recommend updated COVID vaccines for those six months and older	Jun. 27	RE
Novavax applies to the EMA for its Covid vaccine from age 12	Jun. 24	CF
Novavax Seeks EU Authorization for Updated Covid-19 Vaccine	Jun. 24	MT
Novavax Files Emergency Use Authorization Amendment For Updated COVID-19 Vaccine	Jun. 14	MT
FDA asks COVID vaccine makers to target KP.2 strain with updated shots	Jun. 14	RE
Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine	Jun. 14	CI
COVID shots should target JN.1 variants in 2024-25 campaign, US FDA says	Jun. 07	RE
S&P 500, Nasdaq dip on the eve of US payrolls data	Jun. 06	RE
Wall Street mixed as Nvidia retreat hits tech stocks; payrolls data in focus	Jun. 06	RE
Novavax Says FDA Review Target Date Set for Covid-19 Vaccine Biologics License Application	Jun. 06	MT
Novavax Says It Can Deliver Recommended Covid Vaccine in September	Jun. 05	DJ
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say	Jun. 05	RE
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says	Jun. 03	RE
Sanofi and Novavax Announce Co-Exclusive Licensing Agreement to Co-Commercialize Covid-19 Vaccine and Develop Novel Flu-Covid-19 Combination Vaccines	May. 28	CI
Novavax awaits FDA decision on whether its next COVID shot can be offered in US	May. 24	RE
Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024	May. 23	CI
B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	May. 23	MT
Novavax: 1st shipment of R21/MatrixM malaria vaccine	May. 21	CF
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft...	May. 20
Focus on Nvidia	May. 20
Shah Capital ends campaign against Novavax board after Sanofi deal	May. 20	RE

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novavax Surges on $1.2 Billion Sanofi Vaccine Deal

May 10, 2024 at 02:52 pm EDT

More Strategies

Ratings for Novavax, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.12 USD

Average target price

22.8 USD

Spread / Average Target

+50.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVAVAX, INC.	+238.85%	2.12B
MODERNA, INC.	+26.79%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.07%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+32.71%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.82%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.96%	14.52B
MEDPACE HOLDINGS, INC.	+47.88%	13.74B
BIO-TECHNE CORPORATION	+3.24%	12.17B

Other Biotechnology & Medical Research

Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Novavax : An experimental COVID-19 vaccine from Novavax appears to offer strong protection in late-stage UK, South Africa studies

Latest news about Novavax, Inc.

Chart Novavax, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novavax, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research